Yiviva

Executive Summary

Yiviva is a clinical-stage biotechnology company leveraging a proprietary systems biology platform to develop multi-targeted botanical therapeutics for chronic diseases and cancer. Headquartered in New York, the company was founded in 2014 with the vision of addressing complex disease networks more effectively than traditional single-target drugs. Yiviva's approach integrates computational modeling and experimental validation to identify synergistic combinations of natural compounds, optimizing them for safety and efficacy. This platform enables the company to tackle diseases with high unmet medical need, such as oncology and metabolic disorders, by modulating multiple pathways simultaneously. The company's lead programs are in preclinical to Phase 1 development, with a focus on cancer and inflammatory conditions. While the botanical-based strategy offers potential for novel mechanisms and lower toxicity, it also faces regulatory and scientific challenges in standardizing complex mixtures. Yiviva's success hinges on clinical proof-of-concept and its ability to navigate FDA requirements for botanical drugs. With a lean team and plausible funding from grants or partnerships, the company represents an early-stage opportunity with speculative upside. Near-term catalysts include data readouts from ongoing trials and potential licensing deals.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead cancer candidate35% success
• Q2 2026Strategic partnership or licensing agreement with a major pharmaceutical company30% success
• Q4 2026FDA clearance of Investigational New Drug (IND) application for a second product candidate50% success